@hoperugo.bsky.social is discussing the results of the ROSALINE trial, an IIT sponsored by the Institut Jules Bordet that evaluated ROS1 inhibition with neo-adj endocrine therapy in early ILBC #ESMOBreast25 👏🏻 @aftimosp.bsky.social & Soraia Lobo-Martins

Day 2 of #ESMOBreast25 in Munich. Data on ADCs will be presented during Mini Oral session 1 including results on 2️⃣ novel ADCs targeting B7H4 in HR+/HER2- and TNBC: emiltatug ledadotin and puxitatug samrotecan #ESMOAmbassadors @myesmo.bsky.social

Part of the Institut Jules Bordet breast cancer team at #ESMOBreast25 @laubdh.bsky.social

An enthusiast and militant talk by @marleenkok.bsky.social at #ESMOBreast25 on the importance of studying biomarkers for immunotherapy in breast cancer, highlighting the KN522 example #ESMOAmbassadors @myesmo.bsky.social

Sustainable travel 🚆 🌱 🌎 to Munich 🇩🇪 and #ESMOBreast25 #ESMOAmbassadors @myesmo.bsky.social

#AACR25 Cancer Research saves lives 🎗️

What a beautiful presentation @mybsmo by Mireille Langouo about "Lymphocyte Subpopulation Balances as a Blood Biomarker for Immune-Related Adverse Events in Patients Receiving Immune Checkpoint Inhibitor". A study conducted @JulesBordet.

Congratulations to all #YoungOncologists - recipients of the #ESMOImmuno24 ESMO Merit Travel Grant 🏆! 📣 Special shout out to ZAYD 🙌 @zaydtippu.bsky.social - who will be presenting our work: "MANIFEST: A Multiomic Profiling Platform for Immuno-Oncology Biomarker Discovery" Go say hi - Poster: 40P!

When @marianabrandao0.bsky.social makes us travel from Geneva #ESMOImmuno24 to Tomorrowland and the Smurf Village throught a brillant discussion of 3 mini orals about treatment strategies for NSCLC patients. Thank you!

Excellent discussion by @marianabrandao0.bsky.social on treatment of patients with #NSCLC #ESMOImmuno24 Insightful perspectives on recent advances!

👏 to J. Stagg & D. Allard for their work revealing ENT1 as a key driver of adenosine-mediated immunosuppression. This finding offers a promising new target to enhance T cell responses against tumors. 👉full study published in Cancer Research @theaacr.bsky.social ➡️ doi.org/10.1158/0008...

Initiation visit this morning at Institut Jules Bordet of the EmpowHER 303 phase 3 study of anti-HER2 bispecific antibody zanidatamab in combination with chemo vs trastuzumab and chemo in HER2+ MBC. clinicaltrials.gov/study/NCT064... #bcsm